S&P 500
(-0.27%) 4 288.05 points
Dow J
(-0.47%) 33 508 points
Nasdaq
(0.14%) 13 219 points
Oil
(0.44%) $91.19
Gas
(-1.13%) $2.90
Gold
(-0.33%) $1 859.90
Silver
(-1.74%) $22.06
Platinum
(1.41%) 919.60
USD/EUR
(0.06%) 0.946
USD/NOK
(0.11%) 10.71
USD/GBP
(0.08%) 0.820
USD/RUB
(0.00%) 96.48
Picture of a house with link to the home page

Realtime updates for Herantis Pharma Oyj [HRTIS.HE]

Exchange: HEL Sector: Healthcare Industry: Biotechnology
Last Updated29 Sep 2023 @ 11:29
Share On:
50% discount on Stockinvest.us - Use code: Podcast

22.26% € 1.675

Live Chart Being Loaded With Signals

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD...

Stats
Today's Volume 21 674.00
Average Volume 6 488.00
Market Cap 28.38M
P/E 1.690
ATR14 €0.0520 (3.10%)

Herantis Pharma Oyj Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Herantis Pharma Oyj Financials

Annual 2022
Revenue: €0
Gross Profit: €0 (0.00 %)
EPS: €0
Q4 2016
Revenue: €0.00
Gross Profit: €0.00 (0.00 %)
EPS: €-0.440
Q4 2015
Revenue: €800.00
Gross Profit: €0.00 (0.00 %)
EPS: €-0.600
Q2 2014
Revenue: €0.00
Gross Profit: €0.00 (0.00 %)
EPS: €-0.739

Herantis Pharma Oyj

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.

Estimated
 HRTIS.HE Next Dividend
 (Unknown) €0 Probabilty 0 %
Quarter Ratio
 HRTIS.HE 0.00 0.00
Pay Frequency
 HRTIS.HE Insufficient data to determine frequency 0
Yearly Payout
 HRTIS.HE

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

DISCLAIMER:

"Getagraph.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "Getagraph.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.
Total Execution Time: 2.2640750408173 seconds
Number of API calls: 2
Number of DB calls: 9